Recurrent respiratory papillomatosis, or RRP in short, is a rare, non-cancerous viral tumor in the airways caused by the human papillomavirus (HPV) that can potentially be life-threatening. There is no known cure for RRP, and the typical treatment involves frequent surgeries, which do not target the root cause of the disease and often lead to considerable complications.
The company we are profiling today is Precigen Inc. (PGEN), a biopharmaceutical company that is developing a gene therapy for RRP.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com